Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Celcuity Price Performance

Shares of CELC traded down $2.41 during trading hours on Thursday, reaching $112.12. The stock had a trading volume of 875,073 shares, compared to its average volume of 774,929. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. Celcuity, Inc. has a 12 month low of $7.57 and a 12 month high of $120.32. The stock has a market capitalization of $5.19 billion, a PE ratio of -30.55 and a beta of 0.25. The company’s 50-day moving average is $103.64 and its two-hundred day moving average is $70.79.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. Research analysts expect that Celcuity, Inc. will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CELC. Soleus Capital Management L.P. grew its holdings in Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after purchasing an additional 437,696 shares during the period. Vanguard Group Inc. boosted its position in shares of Celcuity by 10.7% during the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after purchasing an additional 220,386 shares in the last quarter. Eventide Asset Management LLC grew its stake in shares of Celcuity by 9.8% in the 2nd quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after buying an additional 123,774 shares during the period. Saturn V Capital Management LP increased its position in Celcuity by 8.4% in the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after buying an additional 91,843 shares in the last quarter. Finally, UBS Group AG raised its stake in Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after buying an additional 769,891 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analysts Set New Price Targets

CELC has been the topic of several recent research reports. Craig Hallum lifted their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. HC Wainwright restated a “neutral” rating and set a $94.00 price target (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a research report on Monday, October 20th. Finally, Stifel Nicolaus increased their price objective on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $105.25.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.